Investigational Drug Information for PF-03715455
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug PF-03715455?
PF-03715455 is an investigational drug.
There have been 4 clinical trials for PF-03715455. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2014.
The most common disease conditions in clinical trials are Lung Diseases, Obstructive, Lung Diseases, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are nineteen US patents protecting this investigational drug and three hundred and fourteen international patents.
Summary for PF-03715455
|US Patent Applications||54|
|WIPO Patent Applications||15|
|Japanese Patent Applications||9|
|Clinical Trial Progress||Phase 1 (2014-11-01)|
Recent Clinical Trials for PF-03715455
|An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease||Pfizer||Phase 2|
|An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma||Pfizer||Phase 2|
|Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers||Pfizer||Phase 1|
Clinical Trial Summary for PF-03715455
Top disease conditions for PF-03715455
Top clinical trial sponsors for PF-03715455
US Patents for PF-03715455
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-03715455||See Plans and Pricing||Autotaxin inhibitors||Novartis AG (Basel, CH)||See Plans and Pricing|
|PF-03715455||See Plans and Pricing||Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors||ASTRAZENECA AB (Sodertalje, SE)||See Plans and Pricing|
|PF-03715455||See Plans and Pricing||Chemical compounds||AstraZeneca AB (Sodertalje, SE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for PF-03715455
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PF-03715455||Australia||AU2014291711||2033-07-18||See Plans and Pricing|
|PF-03715455||Brazil||BR112016000779||2033-07-18||See Plans and Pricing|
|PF-03715455||Canada||CA2918284||2033-07-18||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|